Novel pharmacological strategies to treat cognitive dysfunction in COPD

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic Obstructive Pulmonary Disease (COPD) is a major incurable global health burden and is the 4th largest cause of death worldwide. Up to 60% of COPD patients suffer from cognitive dysfunction (i.e. a brain disorder which affects learning, memory, attention) which often leads to dementia. The reason for this is unknown so the aim of this study is to determine why people with COPD suffer from mental disorders then develop novel treatments to treat these disorders in COPD patients.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $872,455.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chronic obstructive pulmonary disease (COPD) | cognitive dysfunction | lung inflammation | pharmacology | respiratory diseases